Patients with NTRK Fusions Respond to Targeted Therapies.

LOXO-101, which targets proteins encoded by gene fusions involving NTRK1, NTRK2, and NTRK3, and entrectinib, which targets fusion proteins encoded by translocations in ROS1 and ALK, yielded dramatic clinical activity in patients with a variety of cancers in separate phase I trials. The data were presented at the American Association for Cancer Research Annual Meeting 2016, April 16-20, in New Orleans, LA.